TX-MAVENIR
16.6.2021 15:02:03 CEST | Business Wire | Press release
Mavenir, the Network Software Provider building the future of networks with cloud-native software that runs on any cloud and transforms the way the world connects, announced today its campus network in Dallas for 4G/5G. The campus demonstrates network integration across a suite of certified solutions, integration with 3rd party vendors for interoperability testing and a new approach to Open Virtualized Radio Access Network (Open vRAN) Citizens Broadband Radio Service (CBRS)/OnGo® Private Network deployments.
Mavenir’s CBRS/OnGo® certified product offering address macro, enterprise and Industry 4.0 use cases. These solutions are being delivered as an end-to-end private network solution or as part of an Open RAN deployment to help Enterprises, Carriers, Value Added Resellers (VARs), System Integrators (SIs) and Wireless Internet Service Providers (WISPs) take advantage of the CBRS spectrum across the United States.
The Mavenir Private Network solution offering, MAVedge , includes radio and core for full CBRS/OnGo® connectivity across varied applications:
-
MAVair
:
- A full suite of 4G/5G FCC and OnGo® certified Citizen Broadband Service Devices (CBSD): for both indoor and outdoor applications, zero-touch provisioning and analytics.
- Smart poles which include a wide range of capabilities including electric vehicle (EV) charger station, large light-emitting diode (LED) display unit for advertisements, camera, street light and weather station / environmental sensor.
- CBRS/OnGo® Open vRAN: designed with cloud-native virtualization techniques, enables the RAN to flex and adapt based on usage and coverage.
- MAVcore : 4G/5G Evolved Packet Core (EPC), delivered on premise, hybrid and cloud hosted CBRS/OnGo® as a service.
As a pioneer in Open RAN , Mavenir has completed interoperability testing with 3rd party solution providers, including multiple Customer Premises Equipment (CPE), to validate and showcase vendor interoperability and demonstrate how the ecosystem deploys a successful and functional Open vRAN-based private network. The Mavenir campus hosts a private CBRS/OnGo® network for indoor and outdoor interoperability showcasing network Internet of Things (IoT) capabilities, radios and antennas deployed across a variety of smart use cases including smart light poles. Additionally, the campus demonstrates throughput, handover, and full carrier aggregation across both General Authorized Access (GAA) and Priority Access License (PAL) spectrum
“Mavenir is committed to driving interoperability by growing the CBRS/OnGo® ecosystem with device vendors, application providers and network connectivity players”, said Mavenir’s Aniruddho Basu, SVP and GM of Emerging Business. “The Mavenir 4G/5G Campus offers a network showcase Open vRAN and demonstrates open interoperability, test and implementation of end-to-end user applications, including IoT sensor and device connectivity. Putting Mavenir on the map for municipalities, enterprises and Communication Service Providers (CSP) looking to explore the possibilities available by operating a private network.”
About Mavenir:
Mavenir is building the future of networks and pioneering advanced technology, focusing on the vision of a single, software-based automated network that runs on any cloud. As the industry's only end-to-end, cloud-native network software provider, Mavenir is focused on transforming the way the world connects, accelerating software network transformation for 250+ Communications Service Providers in over 120 countries, which serve more than 50% of the world’s subscribers. www.mavenir.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210616005097/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom